Vontobel Holding Ltd. Sells 53,522 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

Vontobel Holding Ltd. cut its holdings in Autolus Therapeutics plc (NASDAQ:AUTL) by 26.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 147,419 shares of the company’s stock after selling 53,522 shares during the period. Vontobel Holding Ltd. owned 0.06% of Autolus Therapeutics worth $346,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Aubrey Capital Management Ltd purchased a new stake in Autolus Therapeutics in the 4th quarter worth approximately $199,000. Dumont & Blake Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 4th quarter valued at about $35,000. Arkadios Wealth Advisors purchased a new stake in Autolus Therapeutics during the 4th quarter valued at about $47,000. Avanza Fonder AB bought a new position in Autolus Therapeutics during the 4th quarter valued at about $75,000. Finally, Hennion & Walsh Asset Management Inc. bought a new position in shares of Autolus Therapeutics in the 4th quarter worth approximately $611,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Stock Performance

Shares of AUTL stock opened at $1.95 on Friday. Autolus Therapeutics plc has a fifty-two week low of $1.87 and a fifty-two week high of $6.70. The firm has a market capitalization of $518.88 million, a price-to-earnings ratio of -1.61 and a beta of 2.02. The stock’s 50-day simple moving average is $2.24 and its 200-day simple moving average is $3.21.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, November 15th. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Needham & Company LLC restated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $10.40.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.